[ Resources ]
Guides, protocols, and articles on research-grade peptides. Free PDF downloads cover starter knowledge, application categories, synthesis & QC, and 2026 research trends. New articles are published regularly. Research use only.
Interactive utilities for research dosing and recovery
Tool
Compute syringe units, concentration, and vial duration for BPC-157, Retatrutide, GHK-Cu, MOTS-c, CJC-1295/Ipamorelin, Semax. Free.
Tool
A short assessment that scores your recovery, finds your primary limiter, and maps it to a research protocol track. Free.
Download the research layer
Starter Guide
Essential knowledge for researchers beginning peptide investigation. Purity standards, handling protocols, safety systems, and a complete reference glossary.
Quick Reference
A researcher's field guide to peptide categories, mechanisms, and therapeutic research areas. Mechanism, application domain, and clinical evidence at a glance.
Technical Reference
Solid-phase peptide synthesis fundamentals, analytical techniques, quality control systems, and troubleshooting protocols for research-grade production.
Intelligence Brief
The state of peptide science: next-generation compounds, AI-accelerated discovery, oral delivery breakthroughs, and the regulatory landscape shaping research access.
Research notes, protocols, and city-specific guides
City Guide
East Java's highland university city. BPOM import rules, delivery across all five districts, and storage guidance for a humid climate.
City Guide
South Sumatra's river port capital. BPOM import rules, Boom Baru shipping logistics, and tropical storage guidance for Palembang researchers.
City Guide
Central Java's provincial capital and main port. BPOM import rules, Tanjung Emas logistics, and tropical storage guidance for Semarang researchers.
City Guide
Eastern Indonesia's main port city, its BPOM import rules, tuna-industry cold-chain overlap, and Universitas Hasanuddin's research capacity.
City Guide
Kualanamu airport and the Port of Belawan handle North Sumatra's cold chain. Import rules, delivery coverage, and tropical storage guidance for Medan.
Comparison
Gene therapy, a myostatin-only antibody, and a broader receptor blocker have each been tested. The three approaches do not produce the same effect size.
Comparison
The body's own antimicrobial peptide against a gastric-derived pentadecapeptide: one has a randomized human trial, the other a wider animal-model record.
Comparison
An 11-minute GHRH pulse against an 8-day albumin-bound analogue. Human trial data, GH response patterns, and regulatory history compared.
Comparison
Two head-to-head randomized trials, SURPASS-2 and SURMOUNT-5, put the drugs against each other directly instead of relying on cross-trial estimates.
Comparison
One amino acid separates them, and nearly every trial, GRAS filing, and newer pain-study result belongs to only one of the two names.
Comparison
A Russian anxiolytic with three documented mechanisms against a Swiss sleep peptide with no identified receptor after almost 50 years. Evidence and handling compared.
Comparison
An upstream KNDy-neuron trigger against a synthetic GnRH decapeptide. IVF trigger data, pulsatile pump therapy evidence, and handling notes compared.
Comparison
A cell-death blocker from Alzheimer's brain tissue against a 2015 exercise and metabolism peptide. Mechanism and head-to-head studies compared.
Comparison
An FDA-approved cardiolipin-binding drug against a mitochondrial-DNA product that just got a non-binding compounding nod. Mechanism and 2026 regulatory status compared.
Comparison
Same receptor, similar GH potency, and one hormone that only one of them leaves untouched. A 1998 swine study and separate human data compared.
Comparison
Two hexapeptides from the same Tulane research program, sharing one receptor. Potency, cortisol response, appetite effects, and regulatory status compared with primary literature.
Comparison
A copper tripeptide with no antimicrobial activity against the only antimicrobial peptide the human body makes on its own. Mechanism and trial evidence compared.
Comparison
A growth hormone fragment that never beat placebo in its largest trial against an FDA-approved GLP-1 agonist with a cardiovascular outcomes trial behind it.
Comparison
A Soviet-era pineal peptide studied for telomerase activation against a 2015 mitochondrial discovery studied for insulin sensitivity. Mechanism and trial evidence compared.
Comparison
One signals through toll-like receptors on immune cells, the other sequesters actin for tissue repair. Mechanism, human trial evidence, and half-life data compared.
Comparison
One is a nonselective MC1R-MC5R agonist that never left Phase 2. The other is an FDA-approved drug. Receptor pharmacology, trial data, and safety compared.
Comparison
One drives angiogenesis through VEGFR2 signaling, the other delivers copper to remodel collagen. Mechanisms, animal evidence, and human trial status compared.
Comparison
Two different fixes for the same IGF-1 binding-protein problem, one by extending the chain, one by shortening it. Potency, receptor selectivity, and clearance data compared.
Comparison
Only one of these GHRH analogues has FDA approval and a completed Phase 3 program. Half-life, dosing, trial evidence, and regulatory status compared.
Comparison
One binds a cardiac receptor and raises cortisol and prolactin with dose. The other stays selective for GH even at high multiples of its dose. Mechanism and trial data compared.
Comparison
Both trace to GHRH(1-29), but an albumin-binding linker stretches CJC-1295's half-life from minutes to days. Mechanism, trial data, and research use compared.
Protocol
Why most research peptides ship as freeze-dried powder instead of pre-mixed liquid, what the stability literature shows, and how reconstitution changes the shelf-life math.
Protocol
What makes a 0.22 micron filter "sterilizing grade," why membranes adsorb some of the peptide during filtration, and how to filter without wasting the batch.
Protocol
Nitrogen and argon backfilling protects peptide vials by displacing headspace oxygen. The mechanism, the pharmaceutical QC evidence, and what changes once a vial is opened.
Protocol
Converting mg/mL and mcg/mL to molarity depends on molecular weight, not just mass. Worked examples, the dilution formula, and the errors that trip up the conversion.
Protocol
Expiry dates come from stability testing on one batch, not a hard rule. FDA shelf-life extension data and peptide kinetic models show what actually predicts post-expiry risk.
Protocol
Why most peptides degrade slowest between pH 3 and 6, why acidic conditions target the Asp-Pro bond specifically, and how BPC-157 breaks the pattern.
Protocol
Needle gauge changes injection pain and handling more than intuition suggests. What three published comparison studies show for research protocols.
Protocol
Purity testing splits into HPLC for separation, mass spectrometry for identity, and amino acid analysis for actual mass. What each one catches.
Protocol
Molecular weight on a COA confirms compound identity and predicts clearance and half-life; here is how to calculate it and read it correctly.
Protocol
Aliquoting divides a reconstituted peptide stock into single-use portions at reconstitution, cutting freeze-thaw damage, tube adsorption, and contamination risk.
Protocol
Absorption studies put subcutaneous peptide bioavailability anywhere from near total to under 1 percent, depending on peptide size and route.
Protocol
How peptide half-life works in research protocols: absorption, distribution, renal clearance, and the pharmacokinetic data behind each mechanism.
Compound Guide
Thymulin research overview: the zinc-dependent thymic peptide mechanism, autoimmune and aging studies, and where the human trial evidence still falls short.
Compound Guide
Tirzepatide research overview covering the dual GIP/GLP-1 receptor mechanism, SURPASS-3 and SURMOUNT-1 trial data showing up to 20.9% weight loss at 72 weeks, and the Mounjaro and Zepbound FDA approvals.
Compound Guide
Semaglutide research overview covering the GLP-1 receptor mechanism, SUSTAIN and STEP trial data showing 14.9% weight loss at 68 weeks, and the SELECT cardiovascular trial (n=17,604) that reduced major adverse cardiac events.
Compound Guide
How researchers isolated the lipolytic tail of growth hormone, the beta3-adrenergic mechanism, animal-study numbers from Ng and Heffernan, and newer osteoarthritis and pain research under the LAT8881 name.
Compound Guide
GHRP-2 research overview covering the GHS-R1a mechanism, pediatric and adult GH secretion trials, a 33-minute terminal half-life in children, appetite data, and pralmorelin's 2004 diagnostic approval in Japan.
Compound Guide
GHRP-6 was the first synthetic hexapeptide shown to release growth hormone, in 1984, 15 years before its receptor's natural ligand, ghrelin, was identified. Covers the human GHRH-dependence data (n=9), the obesity stimulation test, and the appetite effects it shares with ghrelin.
Compound Guide
DSIP is a 1977 Basel discovery with no identified receptor to this day. Covers the rat growth hormone data, conflicting human ACTH studies, and why controlled insomnia trials still disagree.
Compound Guide
Follistatin-344 is an AAV gene therapy construct that blocks myostatin signaling. Covers the 2008 mdx mouse study, the 2009 nonhuman primate trial, and the six-patient Becker muscular dystrophy trial (NCT01519349).
Compound Guide
Thymosin Alpha-1 signals through TLR2/4/9 on dendritic cells. Covers the 1977 Goldstein discovery, the 1998 hepatitis B trial (n=98, 40.6% response), and the split verdict on sepsis: ETASS 2013 (n=361) versus the negative 2025 TESTS trial (n=1,106).
Compound Guide
Kisspeptin signals through KISS1R (GPR54) to control GnRH release. Covers the 2003 Seminara and de Roux genetic discoveries, the KNDy pulse-generator model, sexual dimorphism in LH response, and the 2015 IVF trigger trial (n=60, 62% live birth rate).
Compound Guide
LL-37 is the only human cathelicidin antimicrobial peptide, cleaved from hCAP-18 by proteinase 3. Covers antimicrobial and angiogenesis mechanisms, psoriasis and rosacea immune signaling, and the 2014 venous leg ulcer trial (n=34).
Compound Guide
SS-31 (elamipretide) binds cardiolipin independent of membrane potential. Covers the 2004 Zhao mechanism paper, TAZPOWER and PROGRESS-HF trial data, and the September 2025 FDA approval of Forzinity for Barth syndrome.
Compound Guide
Humanin is a 24-aa peptide from the mtDNA 16S rRNA gene. Covers discovery (Hashimoto 2001, PNAS), Bax-binding and gp130 signaling mechanisms, NOD mouse beta cell data (n=12, 0.7 mg/kg), and Yen 2020 lifespan findings.
Compound Guide
MT-II is a cyclic alpha-MSH analogue developed at the University of Arizona. Covers MC1R/MC4R pharmacology, Wessells 1998 ED trial (n=10, 8/10 erections), tanning studies, side effects, and the PT-141 lineage.
Compound Guide
AOD-9604 is a synthetic C-terminal hGH fragment studied for lipolysis via beta-3 AR upregulation. Phase 2b OPTIONS trial (n=502) failed primary endpoint. GRAS status granted; not FDA approved for any indication.
Compound Guide
Sermorelin (GHRH 1-29 analogue) has an 11-12 minute plasma half-life. FDA approved as Geref in 1997. Mechanism, pediatric trial data (n=110), pharmacokinetics, and comparison to CJC-1295 and tesamorelin reviewed.
Compound Guide
Tesamorelin (Egrifta) is the only FDA-approved GHRH analogue. Phase 3 data in 816 HIV patients showed 15-18% visceral fat reduction at 26 weeks. Mechanism, trials, IGF-1 effects, and evidence scope reviewed.
Compound Guide
Hexarelin (EP-23905) research overview: human trial GH data, cortisol co-stimulation, desensitization profile, cardioprotection via CD36, and comparison to ipamorelin and GHRP-6.
Compound Guide
IGF-1 LR3 research overview: reduced IGFBP binding, PI3K/Akt/mTOR signaling, cell culture applications, and in vivo findings in guinea pig and pig models.
Compound Guide
PT-141 research overview: bremelanotide mechanism at MC3R/MC4R, RECONNECT Phase 3 trial data in 1,267 women, FDA Vyleesi approval, and adverse event profile.
Compound Guide
Epitalon (AEDG) research overview covering telomerase activation findings, 11-31% rodent lifespan data, neurogenic effects, and why human RCT evidence is still absent.
Compound Guide
Selank research overview covering enkephalinase inhibition, GABAergic modulation, BDNF effects, and the limits of the current animal-model evidence base.
Protocol
Cold chain peptide shipping across Indonesia's archipelago: packaging options, inter-island logistics, and arrival inspection for temperature-sensitive compounds.
Protocol
What causes peptide oxidation, which residues are most vulnerable, and practical prevention for research handling and tropical storage conditions.
Protocol
What drives peptide aggregation in reconstituted research solutions, how to detect it early, and practical prevention strategies covering pH, concentration, and storage.
Protocol
Bacteriostatic water mechanism, 28-day beyond-use date, per-draw needle hygiene, and contamination rates from peer-reviewed literature.
Protocol
How to prevent microbial contamination during peptide reconstitution: sterile field setup, stopper disinfection, hand hygiene sequence, and tropical climate adjustments. Literature-backed.
Protocol
How to calculate reconstitution concentration, convert mg to mcg, and determine the correct U-100 syringe draw volume for any research dose. Worked examples.
Protocol
How repeated freeze-thaw cycles degrade reconstituted peptides through aggregation and pH shifts, with stability data and aliquoting protocols.
Protocol
How amino acid composition determines solubility, with step-by-step guidance for aqueous, acidic, and DMSO-based reconstitution.
City Guide
BPOM Special Access Scheme, delivery to all 30 Kota Bandung districts, and storage guidance for the highland tropical climate.
City Guide
BPOM Special Access Scheme, next-day delivery across all DIY regencies, and storage guidance for Yogyakarta's tropical highland climate.
City Guide
BPOM Special Access Scheme, next-day delivery across East Java, and storage guidance for Surabaya's hot-humid tropical climate.
City Guide
BPOM Special Access Scheme requirements, same-day Jabodetabek delivery, and storage guidance for Indonesia's tropical climate.
City Guide
BPOM Special Access Scheme for research-use imports, cold-chain delivery to Canggu, Seminyak, Ubud, Sanur, and Uluwatu, and why Bali's Zone IVb climate demands freezer storage.
Comparison
BDNF neurotrophin pathways versus GABA-A modulation. Two indexed human studies for Semax, one for Selank. Mechanism table, evidence review, and protocol notes.
Comparison
The with-DAC form persists for 5.8-8.1 days via covalent albumin binding; modified GRF 1-29 clears in 30 minutes. Compare GH release patterns and what the human trial data shows.
Comparison
BPC-157 and TB-500 target tissue repair through distinct pathways. Compare mechanisms, evidence base, and research protocol use for these two peptides.
Comparison
Phase 2 retatrutide hit 24.2% weight loss at 48 weeks; Phase 3 tirzepatide 22.5% at 72 weeks. Why the datasets cannot be directly compared, what the GCGR component adds, and when TRIUMPH-5 head-to-head data arrives.
Comparison
Phase 2 retatrutide showed 24.2% weight loss at 48 weeks vs 14.9% for semaglutide in Phase 3. How the receptor mechanisms differ, what the trial designs mean for comparison, and where a head-to-head study stands.
Quality
The handling errors most consistently flagged in peer-reviewed protocols: reconstitution technique, container adsorption, freeze-thaw damage, math errors, and tropical storage.
Protocol
How site cycling prevents lipohypertrophy and maintains absorption consistency. Pharmacokinetic data from four PubMed-cited studies, standard abdomen-thigh-arm patterns, and needle guidance for research protocols.
Protocol
BAC water adds 0.9% benzyl alcohol to extend reconstituted peptide viability to 21 days. Sterile water is preservative-free and single-use. When each diluent applies.
Protocol
How route choice affects Cmax, Tmax, and duration. Leuprolide acetate Phase I data, BPC-157 bioavailability figures, needle gauge, insertion angle, and volume limits.
Compound Guide
Mechanism, wound healing data, cardiac studies, and where the thymosin beta-4 evidence actually ends. Six cited PubMed sources.
Compound Guide
ACTH 4-7 Pro-Gly-Pro mechanism, BDNF upregulation, rat ischemia model findings, two indexed Russian stroke trials, and the only fMRI study in healthy volunteers.
Compound Guide
DAC albumin-binding mechanism, 5.8-8.1 day half-life from the Teichman 2006 JCEM trial, ipamorelin selectivity versus GHRP-6, and where the human evidence stands.
Compound Guide
The 2015 Lee/Cohen founding study, nuclear translocation mechanism, AMPK-AICAR pathway, rodent efficacy data, exercise-induced release, and human plasma aging decline. What the peer-reviewed literature shows as of 2026.
Compound Guide
Collagen synthesis data (10-9 M peak), MMP-2 regulation, wound-healing rodent studies, skin penetration evidence, and the 2015-2018 gene expression analyses. What the peer-reviewed literature shows.
Compound Guide
Triple GLP-1/GIP/glucagon receptor agonist. Phase 2 NEJM data showing 24.2% weight loss at 48 weeks, TRIUMPH Phase 3 results, and comparison with semaglutide and tirzepatide.
Compound Guide
Three decades of rat-model data on GI protection, tendon repair, and angiogenesis. Covers the VEGFR2-Akt-eNOS pathway, FAK-paxillin signaling, and the current state of human trial evidence.
Quality
The purity figure on a COA is an HPLC peak-area ratio, not a mass assay. Covers what it measures, what MS confirms, TFA counter-ions, water content, and purity grade selection.
Protocol
Unit-to-mL conversion, reconstitution calculation, syringe size selection, and measurement accuracy evidence for small-volume subcutaneous peptide protocols.
Protocol
How ICH Zone IV conditions, residual moisture, and tropical humidity affect lyophilized peptide shelf life. Practical two-tier storage setup for Bali and Indonesia researchers.
Protocol
Step-by-step guide to reconstituting lyophilized research peptides. Covers BAC water selection, injection technique, concentration math, and refrigerated storage windows.